HomeInsightsStock Comparison

Marksans Pharma Ltd vs Piramal Pharma Ltd Stock Comparison

Marksans Pharma Ltd vs Piramal Pharma Ltd Stock Comparison

Last Updated on: May 21, 2025

Key Highlights

  • The Latest Trading Price of Marksans Pharma Ltd is ₹ 236.4 as of 21 May 10:43.
  • The P/E Ratio of Marksans Pharma Ltd changed from 4.7 on March 2020 to 21.9 on March 2024 . This represents a CAGR of 36.04% over 5 yearsThe P/E Ratio of Piramal Pharma Ltd changed from 991.5 on March 2024 to 991.5 on March 2024 . This represents a CAGR of 0.00% over 1 years.
  • The Market Cap of Marksans Pharma Ltd changed from ₹ 568.95 crore on March 2020 to ₹ 6867 crore on March 2024 . This represents a CAGR of 64.57% over 5 yearsThe Market Cap of Piramal Pharma Ltd changed from ₹ 8165 crore on March 2023 to ₹ 17052 crore on March 2024 . This represents a CAGR of 44.51% over 2 years.
  • The revenue of Marksans Pharma Ltd for the Mar '25 is ₹ 724.98 crore as compare to the Dec '24 revenue of ₹ 709.7 crore. This represent the growth of 2.15% The revenue of Piramal Pharma Ltd for the Mar '25 is ₹ 2812 crore as compare to the Dec '24 revenue of ₹ 2233 crore. This represent the growth of 25.92%.
  • The ebitda of Marksans Pharma Ltd for the Mar '25 is ₹ 142.27 crore as compare to the Dec '24 ebitda of ₹ 166.61 crore. This represent the decline of -14.61% The ebitda of Piramal Pharma Ltd for the Mar '25 is ₹ 619.24 crore as compare to the Dec '24 ebitda of ₹ 366.92 crore. This represent the growth of 68.77%.
  • The net profit of Marksans Pharma Ltd changed from ₹ 70.44 crore to ₹ 90.73 crore over 8 quarters. This represents a CAGR of 13.49% The net profit of Piramal Pharma Ltd changed from ₹ -98.58 crore to ₹ 153.5 crore over 8 quarters. This represents a CAGR of NaN% .
  • The Dividend Payout of Marksans Pharma Ltd changed from 10.8 % on March 2020 to 20.33 % on March 2024 . This represents a CAGR of 13.49% over 5 yearsThe Dividend Payout of Piramal Pharma Ltd changed from 18.07 % on March 2022 to 3.72 % on March 2024 . This represents a CAGR of -40.95% over 3 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Marksans Pharma Ltd

  • Marksans Pharma Limited was formerly incorporated as Tasc Pharmaceuticals Limited in April, 1982.
  • Pursuant to the Scheme of Amalgamation, name of the Company was changed from Tasc Pharmaceuticals Limited to Marksans Pharma Limited with effect from 10th October, 2005.
  • The Company primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulation.
  • The Company's research and development facilities are located in Verna, Goa and R & D center in Navi Mumbai. In 2004-05, the Company amalgamated with M/s.
  • Marksans Pharma Limited (formerly M/s.

About Piramal Pharma Ltd

  • Piramal Pharma Limited was incorporated on March 4, 2020 as a Public Limited Company and registered with the RoC. The Company offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 17 global facilities and a global distribution network in over 100 countries.
  • It includes an integrated CDMO business, CHG business and ICH business, selling over-the-counter products in India.
  • In addition, it has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market. PPL is a leading pharmaceutical company with global operations, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and global distribution network.
  • It operate under three business verticals - Piramal Pharma Solutions, an integrated contract development and manufacturing organization (CDMO) having a product suite in niche areas such as highly potent Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), antibody drug conjugates, potent sterile injectable, hormonal oral solid dosage forms, biologics and vaccines; Piramal Critical Care, a complex hospital generics (CHG) business in the areas of inhalation anaesthesia, injectable anaesthesia and pain management, intrathecal therapy and other injectable; and India consumer healthcare (ICH) business, selling well-known OTC brands.

Marksans Pharma Ltd News Hub

News

Board of Marksans Pharma recommends final dividend

Marksans Pharma announced that the Board of Directors of the Company at its meeting held o...

Read more

20 May 2025 12:49

News

Relonchem receives marketing authorization for Sennosides 7.5 mg tablets

Marksans Pharma announced that its wholly owned subsidiary Relonchem has received Marketin...

Read more

19 May 2025 13:29

News

Relonchem receives marketing authorization for Gabapentin 50 mg/ml oral solution

Marksans Pharma announced that its wholly owned subsidiary Relonchem has received Marketin...

Read more

15 May 2025 09:45

News

Marksans Pharma to conduct board meeting

Marksans Pharma will hold a meeting of the Board of Directors of the Company on 19 May 202...

Read more

08 May 2025 15:09

News

USFDA concludes inspection of Time-Cap Laboratories' manufacturing facility in New York

Marksans Pharma announced that a current Good Manufacturing Practices (cGMP) inspection wa...

Read more

28 Apr 2025 12:58

News

Marksans Pharma gains as USFDA concludes inspection at New York unit

The inspection took place from April 16 to April 24, 2025, at the subsidiary's manufacturi...

Read more

28 Apr 2025 11:56

Piramal Pharma Ltd News Hub

News

Board of Piramal Pharma recommends final dividend

Piramal Pharma announced that the Board of Directors of the Company at its meeting held on...

Read more

15 May 2025 10:18

News

Piramal Pharma's Turbhe facility successfully completes USFDA inspection

Piramal Pharma announced that the USFDA has issued an Establishment Inspection Report (EIR...

Read more

12 May 2025 12:47

News

Piramal Pharma gains after receiving EIR for Turbhe facility from USFDA

According to the company's exchange filing, the US FDA conducted a general Good Manufactur...

Read more

12 May 2025 15:39

News

Piramal Pharma to conduct board meeting

Piramal Pharma will hold a meeting of the Board of Directors of the Company on 14 May 2025...

Read more

30 Apr 2025 10:45

News

Piramal Pharma's Telangana unit starts production of general anesthesia drug Sevoflurane

This was achieved by creating capacity for Sevoflurane manufacture at the Digwal facility ...

Read more

02 Apr 2025 11:25

News

Piramal Pharma Ltd Spurts 3.8%

Piramal Pharma Ltd rose 3.8% today to trade at Rs 229.65. The BSE Healthcare index is up 0...

Read more

21 Mar 2025 09:30

SWOT Analysis Of Piramal Pharma Ltd

Strength

3

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Marksans Pharma Ltd

Strength

2

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Piramal Pharma Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Marksans Pharma Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Marksans Pharma Ltd and Piramal Pharma Ltd

Which company has a larger market capitalization, Marksans Pharma Ltd or Piramal Pharma Ltd?

Market cap of Marksans Pharma Ltd is 10,724 Cr while Market cap of Piramal Pharma Ltd is 27,277 Cr

What are the key factors driving the stock performance of Marksans Pharma Ltd and Piramal Pharma Ltd?

The stock performance of Marksans Pharma Ltd and Piramal Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Marksans Pharma Ltd and Piramal Pharma Ltd?

As of May 21, 2025, the Marksans Pharma Ltd stock price is INR ₹236.65. On the other hand, Piramal Pharma Ltd stock price is INR ₹205.75.

How do dividend payouts of Marksans Pharma Ltd and Piramal Pharma Ltd compare?

To compare the dividend payouts of Marksans Pharma Ltd and Piramal Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions